Benzylpenicilloyl Polylysine

Identification

Name
Benzylpenicilloyl Polylysine
Accession Number
DB00895  (APRD00822)
Type
Small Molecule
Groups
Approved
Description

Benzylpenicilloyl Polylysine is used as a skin-testing reagent to detect immunoglobulin E antibodies in people with a history of penicillin allergy. The quantitation of in vitro IgE antibodies to the benzylpenicilloyl determinant is a useful tool for evaluating allergic subjects.

Structure
Thumb
Synonyms
  • Benzyl penicilloyl-polylysine
  • Benzylpenicilloyl G polylysine
  • Benzylpenicilloyl-polylysine
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Pre-penInjection60 umol/.25mLIntradermal; SubcutaneousAller Quest Llc1974-07-25Not applicableUs
Pre-penSolution0.000060 mIntradermalAlk Abello, Inc.1975-12-31Not applicableCanada
Categories
UNII
76479814OY
CAS number
31855-75-1
Weight
Average: 626.765
Monoisotopic: 626.309783168
Chemical Formula
C28H46N6O8S
InChI Key
IMPVZRLKKKXMKQ-SGDOCVTFSA-N
InChI
InChI=1S/C22H32N4O6S.C6H14N2O2/c1-22(2)17(21(31)32)26-19(33-22)16(25-15(27)12-13-8-4-3-5-9-13)18(28)24-11-7-6-10-14(23)20(29)30;7-4-2-1-3-5(8)6(9)10/h3-5,8-9,14,16-17,19,26H,6-7,10-12,23H2,1-2H3,(H,24,28)(H,25,27)(H,29,30)(H,31,32);5H,1-4,7-8H2,(H,9,10)/t14-,16?,17+,19-;5-/m11/s1
IUPAC Name
SMILES

Pharmacology

Indication

For use as a adjunct in assessing the risk of administering penicillin (benzylpenicillin or penicillin G).

Structured Indications
Pharmacodynamics

Benylpenicilloyl polylysine is penicilloyl bound to polylysine and is considered to be the major determinant of penicillin metabolism; it is used as a skin-testing reagent to detect immunoglobulin E antibodies in people with a history of penicillin allergy. If skin testing using benzylpenicilloyl and penicillin G (as the sole source of minor determinants) is negative, approximately 97% of patients with a negative skin test will tolerate penicillin.

Mechanism of action

The skin test for penicillin demonstrates the presence or absence of specific IgE antibodies to major and minor penicillin determinants. IgE antibodies to major determinants can be detected by using benzylpenicilloyl polylysine. A penicillin skin test predicts only the presence of IgE antibodies for the major or minor penicillin determinants at the time of application and does not predict the future development of IgE-mediated reactions during subsequent courses of penicillin. Benzylpenicilloyl polylysine reacts specifically with penicilloyl skin sensitizing antibodies (reagins) to produce immediate wheal and flare reactions which may reflect increased risk of allergic reactions to subsequent penicillin therapy.

TargetActionsOrganism
AHigh affinity immunoglobulin epsilon receptor subunit gamma
agonist
Human
AHigh affinity immunoglobulin epsilon receptor subunit alpha
agonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Symptoms of overdose include urticaria, generalized pruritus, local swelling, generalized flushing, anaphylaxis, bronchospasm, fainting and maculopapular eruption.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcenocoumarolBenzylpenicilloyl Polylysine may increase the anticoagulant activities of Acenocoumarol.Approved
AclarubicinThe serum concentration of Aclarubicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Investigational
AcrivastineAcrivastine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
AdrafinilAdrafinil may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Withdrawn
AlcaftadineAlcaftadine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
AlimemazineAlimemazine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Vet Approved
AmibegronAmibegron may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Investigational
AmikacinThe serum concentration of Amikacin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved, Vet Approved
AmitrazAmitraz may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Vet Approved
AmrubicinThe serum concentration of Amrubicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved, Investigational
AnisodamineAnisodamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Investigational
annamycinThe serum concentration of annamycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Investigational
AntazolineAntazoline may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
ApraclonidineApraclonidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
ApramycinThe serum concentration of Apramycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Experimental, Vet Approved
ArbekacinThe serum concentration of Arbekacin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved, Investigational
ArbutamineArbutamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
ArformoterolArformoterol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Investigational
AstemizoleAstemizole may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Withdrawn
AzatadineAzatadine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
AzelastineAzelastine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BamipineBamipine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Experimental
BefunololBefunolol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Experimental
BekanamycinThe serum concentration of Bekanamycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Experimental
BenzatropineBenzatropine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BitolterolBitolterol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Withdrawn
BrimonidineBrimonidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BrompheniramineBrompheniramine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BuclizineBuclizine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
Butyric AcidButyric Acid may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Experimental, Investigational
CarbinoxamineCarbinoxamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
CetirizineCetirizine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
ChloropyramineChloropyramine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
ChlorphenamineChlorphenamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
ChlorphenoxamineChlorphenoxamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Withdrawn
ChlortetracyclineThe therapeutic efficacy of Benzylpenicilloyl Polylysine can be decreased when used in combination with Chlortetracycline.Approved, Investigational, Vet Approved
CimetidineCimetidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
CinnarizineCinnarizine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Investigational
CirazolineCirazoline may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Experimental
ClemastineClemastine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
ClenbuterolClenbuterol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Investigational, Vet Approved
ClonidineClonidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
ClorindioneBenzylpenicilloyl Polylysine may increase the anticoagulant activities of Clorindione.Experimental
CyclizineCyclizine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
CyproheptadineCyproheptadine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
DemeclocyclineThe therapeutic efficacy of Benzylpenicilloyl Polylysine can be decreased when used in combination with Demeclocycline.Approved
DesloratadineDesloratadine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Investigational
DetomidineDetomidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Vet Approved
DexbrompheniramineDexbrompheniramine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
DexchlorpheniramineDexchlorpheniramine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Experimental, Investigational
Dexchlorpheniramine maleateDexchlorpheniramine maleate may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
DexmedetomidineDexmedetomidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Vet Approved
DibekacinThe serum concentration of Dibekacin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Experimental
DicoumarolBenzylpenicilloyl Polylysine may increase the anticoagulant activities of Dicoumarol.Approved
DihydrostreptomycinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Investigational, Vet Approved
DimenhydrinateDimenhydrinate may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
DimetindeneDimetindene may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Investigational
DimetotiazineDimetotiazine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
DiphenadioneBenzylpenicilloyl Polylysine may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineDiphenhydramine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
DipivefrinDipivefrin may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
DobutamineDobutamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
DopexamineDopexamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Investigational
DoxepinDoxepin may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved, Investigational
DoxycyclineThe therapeutic efficacy of Benzylpenicilloyl Polylysine can be decreased when used in combination with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Vet Approved
DroxidopaDroxidopa may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Investigational
EbastineEbastine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Investigational
EmedastineEmedastine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
EphedrineEphedrine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
EpinastineEpinastine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Investigational
EpinephrineEpinephrine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Vet Approved
EpirubicinThe serum concentration of Epirubicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
ErgotamineErgotamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
EsmirtazapineEsmirtazapine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Investigational
EthopropazineEthopropazine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
Ethyl biscoumacetateBenzylpenicilloyl Polylysine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtilefrineEtilefrine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Withdrawn
FamotidineFamotidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
FenoterolFenoterol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Investigational
FexofenadineFexofenadine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
FluindioneBenzylpenicilloyl Polylysine may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineFlunarizine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
FormoterolFormoterol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Investigational
FramycetinThe serum concentration of Framycetin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
GeneticinThe serum concentration of Geneticin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Experimental
GentamicinThe serum concentration of Gentamicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved, Vet Approved
GENTAMICIN C1AThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Benzylpenicilloyl Polylysine.Experimental
GPX-150The serum concentration of GPX-150 can be decreased when it is combined with Benzylpenicilloyl Polylysine.Investigational
GuanabenzGuanabenz may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Investigational
GuanfacineGuanfacine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Investigational
HexoprenalineHexoprenaline may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Withdrawn
HigenamineHigenamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Investigational
HydroxyzineHydroxyzine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
Hygromycin BThe serum concentration of Hygromycin B can be decreased when it is combined with Benzylpenicilloyl Polylysine.Vet Approved
IdarubicinThe serum concentration of Idarubicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
INNO-206The serum concentration of INNO-206 can be decreased when it is combined with Benzylpenicilloyl Polylysine.Investigational
IsepamicinThe serum concentration of Isepamicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Experimental
IsoetarineIsoetarine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
IsoprenalineIsoprenaline may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
IsothipendylIsothipendyl may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
IsoxsuprineIsoxsuprine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Withdrawn
KanamycinThe serum concentration of Kanamycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved, Investigational, Vet Approved
KetotifenKetotifen may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
LafutidineLafutidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Investigational
LavoltidineLavoltidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Investigational
LevocabastineLevocabastine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
LevocetirizineLevocetirizine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
LodoxamideLodoxamide may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
LofexidineLofexidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Investigational
LoratadineLoratadine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
MeclizineMeclizine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
MedetomidineMedetomidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Vet Approved
MephentermineMephentermine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
MepyramineMepyramine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Vet Approved
MequitazineMequitazine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
MetaraminolMetaraminol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Investigational
MethapyrileneMethapyrilene may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Benzylpenicilloyl Polylysine.Approved
MethoxamineMethoxamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Investigational
MethoxyphenamineMethoxyphenamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Experimental
MethyldopaMethyldopa may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
MetiamideMetiamide may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Experimental
MetrizamideThe serum concentration of Metrizamide can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
MianserinMianserin may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Investigational
MicronomicinThe serum concentration of Micronomicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Experimental
MidodrineMidodrine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
MinocyclineThe therapeutic efficacy of Benzylpenicilloyl Polylysine can be decreased when used in combination with Minocycline.Approved, Investigational
MirabegronMirabegron may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
MirtazapineMirtazapine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
MizolastineMizolastine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Investigational
Mycophenolic acidThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Benzylpenicilloyl Polylysine resulting in a loss in efficacy.Approved
NaphazolineNaphazoline may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
NeamineThe serum concentration of Neamine can be decreased when it is combined with Benzylpenicilloyl Polylysine.Experimental
NebivololNebivolol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Investigational
NeomycinThe serum concentration of Neomycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved, Vet Approved
NetilmicinThe serum concentration of Netilmicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved, Investigational
NizatidineNizatidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
NorepinephrineNorepinephrine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
NorfenefrineNorfenefrine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Experimental
NylidrinNylidrin may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
OctopamineOctopamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Experimental
OlodaterolOlodaterol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
OlopatadineOlopatadine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
OrciprenalineOrciprenaline may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
OxatomideOxatomide may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Investigational
OxyfedrineOxyfedrine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Experimental
OxymetazolineOxymetazoline may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
OzagrelOzagrel may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Investigational
ParomomycinThe serum concentration of Paromomycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved, Investigational
PemirolastPemirolast may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Investigational
PhenindaminePhenindamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
PhenindioneBenzylpenicilloyl Polylysine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniraminePheniramine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
PhenprocoumonBenzylpenicilloyl Polylysine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylephrinePhenylephrine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
PhenylpropanolaminePhenylpropanolamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Vet Approved, Withdrawn
PirarubicinThe serum concentration of Pirarubicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Investigational
PirbuterolPirbuterol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
PlazomicinThe serum concentration of Plazomicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Investigational
PlicamycinThe serum concentration of Plicamycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved, Investigational, Withdrawn
PrenalterolPrenalterol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Experimental
ProbenecidThe serum concentration of Benzylpenicilloyl Polylysine can be increased when it is combined with Probenecid.Approved
ProcaterolProcaterol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Investigational
ProchlorperazineProchlorperazine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Vet Approved
PromethazinePromethazine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
PseudoephedrinePseudoephedrine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
PuromycinThe serum concentration of Puromycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Experimental
QuifenadineQuifenadine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Experimental
RacepinephrineRacepinephrine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
RactopamineRactopamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Vet Approved
RanitidineRanitidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
ReproterolReproterol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Investigational
RibostamycinThe serum concentration of Ribostamycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved, Investigational
RilmenidineRilmenidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Investigational
RimiterolRimiterol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Experimental
RitobegronRitobegron may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Investigational
RitodrineRitodrine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Investigational
RomifidineRomifidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Vet Approved
Roxatidine acetateRoxatidine acetate may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Investigational
SabarubicinThe serum concentration of Sabarubicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Investigational
SalbutamolSalbutamol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Vet Approved
SalmeterolSalmeterol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
SisomicinThe serum concentration of Sisomicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Investigational
SolabegronSolabegron may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Investigational
SP1049CThe serum concentration of SP1049C can be decreased when it is combined with Benzylpenicilloyl Polylysine.Investigational
SpectinomycinThe serum concentration of Spectinomycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved, Investigational, Vet Approved
StreptomycinThe serum concentration of Streptomycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved, Vet Approved
StreptozocinThe serum concentration of Streptozocin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
SynephrineSynephrine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Experimental
TerbutalineTerbutaline may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
TerfenadineTerfenadine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Withdrawn
TesmilifeneTesmilifene may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Investigational
ThonzylamineThonzylamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
TioclomarolBenzylpenicilloyl Polylysine may increase the anticoagulant activities of Tioclomarol.Experimental
TizanidineTizanidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
TobramycinThe serum concentration of Tobramycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved, Investigational
TranilastTranilast may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Investigational
TretoquinolTretoquinol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Experimental
TripelennamineTripelennamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Vet Approved
TriprolidineTriprolidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
TritoqualineTritoqualine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Experimental
TulobuterolTulobuterol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Investigational
ValrubicinThe serum concentration of Valrubicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
WarfarinBenzylpenicilloyl Polylysine may increase the anticoagulant activities of Warfarin.Approved
XamoterolXamoterol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Experimental
XylazineXylazine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Vet Approved
YM-178YM-178 may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Investigational
Zoptarelin doxorubicinThe serum concentration of Zoptarelin doxorubicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Investigational
ZorubicinThe serum concentration of Zorubicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB15032
PubChem Compound
45266800
PubChem Substance
46505002
ChemSpider
26331550
ChEBI
59297
ChEMBL
CHEMBL1201779
Therapeutic Targets Database
DAP001314
PharmGKB
PA164754810
ATC Codes
J01CR50 — Combinations of penicillins
AHFS Codes
  • 36:30.00 — Drug Hypersensitivity

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedDiagnosticHistory of IgE Dependent Reaction to a Penicillin Product1

Pharmacoeconomics

Manufacturers
  • Allerquest llc
Packagers
Dosage forms
FormRouteStrength
InjectionIntradermal; Subcutaneous60 umol/.25mL
SolutionIntradermal0.000060 m
Prices
Unit descriptionCostUnit
Pre-pen ampul72.0USD ampul
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP-0.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0658 mg/mLALOGPS
logP-0.89ALOGPS
logP-3.8ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)2.04ChemAxon
pKa (Strongest Basic)9.53ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area170.85 Å2ChemAxon
Rotatable Bond Count17ChemAxon
Refractivity122.22 m3·mol-1ChemAxon
Polarizability50.31 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Igg binding
Specific Function
Associates with a variety of FcR alpha chains to form a functional signaling complex. Regulates several aspects of the immune response. The gamma subunit has a critical role in allowing the IgE Fc ...
Gene Name
FCER1G
Uniprot ID
P30273
Uniprot Name
High affinity immunoglobulin epsilon receptor subunit gamma
Molecular Weight
9667.355 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Chandra RK, Joglekar SA, Tomas E: Penicillin allergy: anti-penicillin IgE antibodies and immediate hypersensitivity skin reactions employing major and minor determinants of penicillin. Arch Dis Child. 1980 Nov;55(11):857-60. [PubMed:7436456]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Ige receptor activity
Specific Function
Binds to the Fc region of immunoglobulins epsilon. High affinity receptor. Responsible for initiating the allergic response. Binding of allergen to receptor-bound IgE leads to cell activation and t...
Gene Name
FCER1A
Uniprot ID
P12319
Uniprot Name
High affinity immunoglobulin epsilon receptor subunit alpha
Molecular Weight
29595.67 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Chandra RK, Joglekar SA, Tomas E: Penicillin allergy: anti-penicillin IgE antibodies and immediate hypersensitivity skin reactions employing major and minor determinants of penicillin. Arch Dis Child. 1980 Nov;55(11):857-60. [PubMed:7436456]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18